U.S. FDA (Food and Drug Administration) has approved the Pitavastatin (Lival, Kowa Pharmaceuticals America Inc), a new cholesterol-lowering drug for the treatment of primary hypercholesterolemia and combined dyslipidemia. Pitavastatin is the newest class of drugs, joining atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin and fluvastatin in the crowded market of statins. The drug is expected to launch in the U.S. in early 2010 and will be available in three low dose: 1 mg, 2 mg and 4 mg. It has been available in Japan since 2003, and is also available in South Korea, Thailand and China. , the FDA said the drug was approved on the basis of the results of five clinical trials that show that the Pitavastatin as safe and effective as other statins on the market. A press release issued by the company points out that studies showed that the drug is particularly effective in special populations, including the elderly, patients with diabetes and those at increased cardiovascular risk.
Source: archiCentral
0 comments:
Post a Comment